drugset / Trial / NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Timeline
- Start
- 2026-02-04
- Primary completion
- 2028-12-12
- Completion
- 2031-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-79635322 | Unknown | — | Subcutaneous |
| Comparator | Teclistamab | Monoclonal antibody | — | Subcutaneous |